Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands

There is limited evidence on the costs associated with ipilimumab. We investigated healthcare costs of all Dutch patients with advanced cutaneous melanoma who were treated with ipilimumab. Data were retrieved from the nation-wide Dutch Melanoma Treatment Registry. Costs were determined by applying u...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Anti-cancer drugs 2018-07, Vol.29 (6), p.579-588
Hauptverfasser:	Franken, Margreet G, Leeneman, Brenda, Jochems, Anouk, Schouwenburg, Maartje G, Aarts, Maureen J.B, van Akkooi, Alexander C.J, van den Berkmortel, Franchette W.P.J, van den Eertwegh, Alfonsus J.M, de Groot, Jan Willem B, van der Hoeven, Koos J.M, Hospers, Geke A.P, Kapiteijn, Ellen, Koornstra, Rutger, Kruit, Wim H.J, Louwman, Marieke W.J, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P.M, ten Tije, Albert J, Vreugdenhil, Gerard, Wouters, Michel W.J.M, van Zeijl, Michiel, Haanen, John B.A.G, Uyl-de Groot, Carin A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Drug Costs Female Health Care Costs Humans Ipilimumab - economics Ipilimumab - therapeutic use Male Melanoma - drug therapy Melanoma - economics Melanoma, Cutaneous Malignant Middle Aged Netherlands Registries Skin Neoplasms - drug therapy Skin Neoplasms - economics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!